PL3236961T3 - Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego - Google Patents
Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwegoInfo
- Publication number
- PL3236961T3 PL3236961T3 PL16776857T PL16776857T PL3236961T3 PL 3236961 T3 PL3236961 T3 PL 3236961T3 PL 16776857 T PL16776857 T PL 16776857T PL 16776857 T PL16776857 T PL 16776857T PL 3236961 T3 PL3236961 T3 PL 3236961T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- pharmaceutical composition
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150049215 | 2015-04-07 | ||
| KR1020150106779A KR20160120157A (ko) | 2015-04-07 | 2015-07-28 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
| EP16776857.1A EP3236961B1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical composition for preventing or treating cancer |
| PCT/KR2016/003602 WO2016163754A1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical composition for preventing or treating cancer and method using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3236961T3 true PL3236961T3 (pl) | 2020-11-30 |
Family
ID=57250106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16776857T PL3236961T3 (pl) | 2015-04-07 | 2016-04-06 | Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10265306B2 (pl) |
| EP (2) | EP3236961B1 (pl) |
| JP (1) | JP6511630B2 (pl) |
| KR (2) | KR20160120157A (pl) |
| CN (1) | CN107223054B (pl) |
| CA (1) | CA2975995C (pl) |
| DK (1) | DK3236961T3 (pl) |
| ES (1) | ES2819909T3 (pl) |
| HU (1) | HUE051563T2 (pl) |
| PL (1) | PL3236961T3 (pl) |
| PT (1) | PT3236961T (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210016059A (ko) * | 2018-06-27 | 2021-02-10 | 주식회사 메드팩토 | 높은 수준의 tgf-b 반응 시그니처를 발현하는 암 환자를 진단 및 치료하는 방법 |
| CA3227334A1 (en) * | 2021-07-28 | 2023-02-02 | Tiumbio Co., Ltd. | Pharmaceutical composition for preventing or treating tumor, and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1758610E (pt) * | 2004-05-20 | 2012-10-01 | Zymogenetics Inc | Métodos para o tratamento de cancro utilizando terapia com il-21 e anticorpos monoclonais |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US20150086584A1 (en) * | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| AU2014276440A1 (en) * | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
-
2015
- 2015-07-28 KR KR1020150106779A patent/KR20160120157A/ko active Search and Examination
-
2016
- 2016-04-06 CA CA2975995A patent/CA2975995C/en active Active
- 2016-04-06 EP EP16776857.1A patent/EP3236961B1/en active Active
- 2016-04-06 HU HUE16776857A patent/HUE051563T2/hu unknown
- 2016-04-06 CN CN201680009490.9A patent/CN107223054B/zh active Active
- 2016-04-06 US US15/549,513 patent/US10265306B2/en active Active
- 2016-04-06 PT PT167768571T patent/PT3236961T/pt unknown
- 2016-04-06 EP EP20177845.3A patent/EP3721905A1/en active Pending
- 2016-04-06 JP JP2017557261A patent/JP6511630B2/ja active Active
- 2016-04-06 PL PL16776857T patent/PL3236961T3/pl unknown
- 2016-04-06 ES ES16776857T patent/ES2819909T3/es active Active
- 2016-04-06 DK DK16776857.1T patent/DK3236961T3/da active
-
2017
- 2017-10-25 KR KR1020170139244A patent/KR102167193B1/ko active IP Right Grant
-
2019
- 2019-02-19 US US16/279,733 patent/US10632110B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017017064A8 (pt) | 2020-08-11 |
| EP3236961B1 (en) | 2020-07-08 |
| US20190175569A1 (en) | 2019-06-13 |
| US10632110B2 (en) | 2020-04-28 |
| KR20170123593A (ko) | 2017-11-08 |
| DK3236961T3 (da) | 2020-09-28 |
| EP3236961A1 (en) | 2017-11-01 |
| CA2975995C (en) | 2020-07-14 |
| HUE051563T2 (hu) | 2021-03-01 |
| JP6511630B2 (ja) | 2019-05-15 |
| CN107223054A (zh) | 2017-09-29 |
| PT3236961T (pt) | 2020-09-24 |
| US10265306B2 (en) | 2019-04-23 |
| CN107223054B (zh) | 2020-05-19 |
| EP3236961A4 (en) | 2018-07-11 |
| JP2018506580A (ja) | 2018-03-08 |
| US20180021317A1 (en) | 2018-01-25 |
| KR20160120157A (ko) | 2016-10-17 |
| BR112017017064A2 (pt) | 2018-04-10 |
| EP3721905A1 (en) | 2020-10-14 |
| ES2819909T3 (es) | 2021-04-19 |
| KR102167193B1 (ko) | 2020-10-19 |
| CA2975995A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3431105T3 (pl) | Kompozycja lecznicza do leczenia raka | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| IL268416A (en) | Pharmaceutical combinations for cancer treatment | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| PL3129378T3 (pl) | Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| HK1232128A1 (zh) | 用於預防或治療皮疹的藥物組合物 | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| PT3290051T (pt) | Composição farmacêutica para o tratamento e/ou prevenção de cancro | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
| ZA201707024B (en) | Cancer treatment composition | |
| PL3236961T3 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego | |
| EP3372233A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
| SG11201913808SA (en) | Pharmaceutical composition for preventing or treating osteoarthritis | |
| IL255167A0 (en) | Compounds for the treatment of cancer | |
| EP3388067A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER |